Nouscom
PrivateLast Round
Series D
Oct 19, 2026
Total Funding Raised
$361.6M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Nouscom operates in Healthcare & Life Sciences and is based in Basel. Its latest recorded funding round was a Series D round in October 2026.
Nouscom is a biotechnology company that develops engineered viral vector vaccines for cancer treatment.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nouscom Comparables
Compare Nouscom with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| cecava GmbH | 80% | |
| Valo Therapeutics | 79% | |
| Elicio Therapeutics | 78% |
For institutional investors. Book with your work email.
Nouscom Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Oct 19, 2026 | ||||
| Series C | Mar 21, 2024 | ||||
| Series C | Nov 14, 2023 | ||||
| Series B | Nov 6, 2017 | ||||
| Series A | May 17, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nouscom Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series C, Series B, Series A, Series D |
| XGEN Venture | Series C, Series D |
| Andera Partners | Series D, Series C |
| Neva SGR | Series D |
| M Ventures | Series C, Series D |
| Indaco Venture Partners SGR | Series C, Series D |
| 5AM Ventures | Series B, Series C, Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 19, 2026
$135M round led by M Ventures and Revelation Partners
- Mar 21, 2024
$82M round led by Andera Partners and M Ventures.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- promotesNov 2, 2026
Nouscom promotes Loredana Siani, previously Senior Vice President of Technical CMC, to Chief Technology Officer on Nov 2nd '26, with responsibility for Chemistry, Manufacturing, and Controls, commercial-scale manufacturing, and technical operations.
- promotesNov 2, 2026
Nouscom promotes Concetta Baldo to Head of Clinical Operations, where she leads global clinical development programs ahead of the registration-enabling trial and brings more than 15 years of clinical research and operations experience.
- hiresOct 19, 2026
Nouscom hires Marina Udier as chief operating officer in Switzerland in 2016; she becomes interim chief executive in May 2019 and later holds the role permanently.
- is_developingOct 19, 2026
In Oct '26, Nouscom is developing NOUS-209, an off-the-shelf cancer immunotherapy designed to train the immune system to recognize and attack cancerous and precancerous cells.
- receives_financingOct 19, 2026
In Nov '26, Nouscom receives $134M in Series D financing, with Neva SGR entering as a new investor to support NOUS-209's advancement into a registration-enabling trial and commercial-scale manufacturing.
For institutional investors. Book with your work email.
Nouscom Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nouscom's valuation, stock price, and market status.
Is Nouscom a public or private company?
Nouscom is a private company.
What is the current stock price of Nouscom?
Nouscom is a private company, so its shares have no public market price. Caplight tracks Nouscom's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nouscom worth (valuation)?
Valuation information for Nouscom is not publicly available.
Can I buy Nouscom stock?
Nouscom shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nouscom's last funding round?
Nouscom's most recent funding round was Series D on October 19, 2026.
Who are the main investors in Nouscom?
Key investors in Nouscom include Andera Partners, M Ventures, Versant Ventures, Abingworth, Revelation Partners.
Will Nouscom IPO soon?
No public IPO plans have been announced for Nouscom.
How can I track Nouscom secondary market activity?
Caplight tracks bids, offers, and trades in Nouscom's shares on secondary markets.